There is an epidemic of obesity, insulin resistance and cardiovascular disease. Adipose tissue plays a major metabolic role and produces hormones with important physiological effects. In vitro studies remove regulatory factors, such as blood flow, making results difficult to interpret, and animal studies cannot necessarily be extrapolated to humans. Fortunately, adipose tissue can be studied in vivo with microdialysis, adipose tissue vein cannulation, measurement of blood flow using 133Xenon washout, stable isotope tracers and biopsies. In vivo studies have shown that adipose tissue is an efficient buffer against the postprandial flux of non-esterified fatty acids (NEFA) in the circulation, protecting other tissues. When there is excess adipose tissue, this buffering effect may be impaired. The postprandial blood flow response is also reduced, potentially causing an atherogenic lipid profile and atheroma. A systems biology approach, combining in vivo techniques with genomics, proteomics and metabolomics, will clarify links between adipose tissue and vascular disease.
1. Anon.Obesity: preventing and managing the global epidemic. WHO Technical Report Series2000;894(i–xii):1–253.
2.
2. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC.Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care1994;17:961–9.
3.
3. Colditz GA, Willett WC, Rotnitzky A, Manson JE.Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med1995;122:481–6.
4.
4. Lew EA, Garfinkel L.Variations in mortality by weight among 750, 000 men and women. J Chronic Dis1979;32:563–76.
5.
5. An overview of insulin resistance. Flier JS, ed. Chichester: Wiley1993;1–8.
6.
6. Reaven GM.Pathophysiology of insulin resistance in human disease. Physiol Rev1995;75:473–86.
7.
7. Kannel WB.Lipids, diabetes and coronary heart disease: insights from the Framingham study. Am Heart J1985;110:1100–07.
8.
8. Turner RC, Millns H, Neil HAW et al.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). Br Med J1998;316:823–8.
9.
9. Frayn KN, Khan K, Coppack SW, Elia M.Amino acid metabolism in human subcutaneous adipose tissue in vivo. Clin Sci1991;80:471–4.
10.
10. Coppack SW, Frayn KN, Humphreys SM, Whyte PL, Hockaday TDR.Arteriovenous differences across human adipose and forearm tissues after overnight fast. Metabolism1990;39:3384–90.
11.
11. Frayn KN, Humphreys SM, Coppack SW.Fuel selection in white adipose tissue. Proc Nut Soc1995;54:177–89.
12.
12. Frayn KN, Coppack SW, Humphreys SM, Whyte PL.Metabolic characteristics of human adipose tissue in vivo. Clin Sci1989;76:509–16.
13.
13. Coppack SW, Frayn KN, Whyte PL, Humphreys SM.Carbohydrate metabolism in human adipose tissue in vivo. Biochem Soc Trans1989;17:145–6.
14.
14. Marin P, Rebuffe-Scrive M, Smith U, Bjorntorp P.Glucose uptake in human adipose tissue. Metabolism1987;36:1154–60.
15.
15. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM.Positional cloning of the mouse obese gene and its human homologue. Nature1994;372:425–32.
16.
16. Schwartz MW, Baskin DG, Bukowski TR et al.Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes1996;45:531–5.
17.
17. Minokoshi Y, Kahn BB.Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem Soc Trans2003;31(Pt 1):196–201.
18.
18. Pajvani UB, Du X, Combs TP et al.Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem2003;278:9073–85.
19.
19. Fruebis J, Tsao TS, Javorschi S et al.Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA2001;98:2005–10.
20.
20. Menzaghi C, Ercolino T, Di Paola R et al.A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes2002;51:2306–12.
21.
21. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE.The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med2001;7:947–53.
22.
22. Combs TP, Pajvani UB, Berg AH et al.A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology2004;145:367–83.
23.
23. Steppan CM, Bailey ST, Bhat S et al.The hormone resistin links obesity to diabetes. Nature2001;409:307–12.
25. Hotamisligil GS, Shargill NS, Spiegelman BM.Adipose expression of tumour necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science1993;259:87–91.
26.
26. Petit F, Bagby GJ, Lang CH.Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. Am J Physiol1995;268(2 Pt 1):E219–E228.
27.
27. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS.Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature1997;389:610–14.
28.
28. Luc G, Bard JM, Juhan-Vague I et al.C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol2003;23:1255–61.
29.
29. Ross R.Atherosclerosis-an inflammatory disease. N Engl J Med1999;340:115–26.
30.
30. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK.Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis1986;6:131–8.
31.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997;336:973–9.
32.
32. Muscari A, Bozzoli C, Puddu GM et al.Association of serum C3 levels with the risk of myocardial infarction. Am J Med1995;98:357–64.
33.
33. Weyer C, Tataranni PA, Pratley RE.Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care2000;23:779–85.
34.
34. Engeli S, Schling P, Gorzelniak K et al.The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol2003;35:807–25.
35.
35. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS.Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension1992;19:339–44.
36.
36. Jonsson JR, Game PA, Head RJ, Frewin DB.The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press1994;3(1–2):72–5.
37.
37. Caulfield M, Lavender P, Newell-Price J, Kamdar S, Farrall M, Clark AJ.Angiotensinogen in human essential hypertension. Hypertension1996;28:1123–5.
38.
38. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al.Molecular basis of human hypertension: role of angiotensinogen. Cell1992;71:169–80.
39.
39. Ward K, Hata A, Jeunemaitre X et al.A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet1993;4(1):59–61.
40.
40. Watt GC, Harrap SB, Foy CJ et al.Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. J Hypertens1992;10:473–82.
41.
41. Kimura S, Mullins JJ, Bunnemann B et al.High blood pressure in transgenic mice carrying the rat angiotensinogen gene. Eur Mol Biol Org J1992;11:821–7.
42.
42. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH.The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest1995;95:948–53.
43.
43. Forrester T, McFarlane-Anderson N, Bennet F et al.Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica.J Hypertens1996;14:315–21.
44.
44. Hegele RA, Brunt JH, Connelly PW.Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation1995;92:1089–93.
45.
45. Skurk T, Lee YM, Hauner H.Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension2001;37:1336–40.
46.
46. Hamsten A, de Faire U, Walldius G et al.Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet1987;2(8549):3–9.
47.
47. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG.Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation1996;94:2057–63.
48.
48. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I.Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes1997;46:860–7.
49.
49. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P.Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia1998;41(1):65–71.
50.
50. Skurk T, Hauner H.Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord2004;28:1357–64.
51.
51. Giltay EJ, Elbers JM, Gooren LJ et al.Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol1998;18:1716–22.
52.
52. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P.Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord1998;22:312–17.
53.
53. Landin K, Stigendal L, Eriksson E et al.Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism1990;39:1044–8.
54.
54. Ungerstedt U.Microdialysis — principles and applications for studies in animals and man. J Intern Med1991;230:365–73.
55.
55. Lonnroth P, Jansson PA, Smith U.A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol1987;253(2 Pt 1):E228–E231.
56.
56. Arner P, Bolinder J.Microdialysis of adipose tissue. J Int Med1991;230:381–6.
57.
57. Summers LK, Arner P, Ilic V, Clark ML, Humphreys SM, Frayn KN.Adipose tissue metabolism in the postprandial period; microdialysis and arteriovenous techniques compared. Am J Physiol1998;274:E651–E655.
58.
58. Frayn KN, Coppack SW, Humphreys SM.Subcutaneous adipose tissue metabolism studied by local catheterization. Int J Obes1993;17 (suppl 3):S18–S21.
59.
59. Simonsen L, Bülow J, Madsen J.Adipose tissue metabolism in humans determined by vein catheterization and microdialysis techniques. Am J Physiol1994;266:E357–E365.
60.
60. Hagström E, Arner P, Ungerstedt U, Bolinder J.Subcutaneous adipose tissue: a source of lactate production after glucose ingestion in humans. Am J Physiol1990;258:E888–E893.
61.
61. Jansson PA, Smith U, Lönnroth P.Evidence for lactate production by human adipose tissue in vivo. Diabetologia1990;33:253–6.
62.
62. Bülow J, Madsen J.Influence of blood flow on fatty acid mobilization from lipolytically active adipose tissue. Pflügers Arch1981;390:169–74.
63.
63. Coppack SW, Fisher RM, Gibbons GF et al.Postprandial substrate deposition in human forearm and adipose tissues in vivo. Clin Sci1990;79:339–48.
64.
64. Galitzky J, Lafontan M, Nordenström J, Arner P.Role of vascular alpha-2 adrenoceptors in regulating lipid mobilisation from human adipose tissue.J Clin Invest1993;91:1997–2003.
65.
65. Samra JS, Frayn KN, Giddings JA, Clark ML, Macdonald IA.Modification and validation of a commercially available portable detector for measurement of adipose tissue blood flow. Clin Physiol1995;15:241–8.
66.
66. Simonsen L, Bülow J, Astrup A, Madsen J, Christensen NJ.Diet-induced changes in subcutaneous adipose tissue blood flow in man: effect of beta-adrenoceptor inhibition. Acta Physiol Scand1990;139:341–6.
67.
67. Butler PC, Home PD.The measurement of metabolite exchange across muscle beds. Baillière's Clinical Endocrinology and Metabolism1987;1:863–78.
68.
68. Haggendal E, Steen B, Svanborg A.Measurement of blood flow through human abdominal subcutaneous fat tissue by local injection of radioactive xenon. Acta Med Scand1967;181:215–17.
69.
69. Larsen OA, Lassen NA, Quaade F.Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand1966;66:337–45.
70.
70. Nielsen SL.Measurement of blood flow in adipose tissue from the washout of 133-xenon after atraumatic labelling. Acta Physiol Scand1972;84:187–96.
71.
71. Kety SS.Measurement of regional circulation by the local clearance of radioactive sodium. Am Heart J1949;38:321–8.
72.
72. Greenhalgh PM, Jones JR, Yudkin JS.The 57 mm thermal clearance probe: a non-invasive tool for measuring subcutaneous blood flow. Clin Sci1989;77:121–7.
73.
73. Virtanen KA, Lonnroth P, Parkkola R et al.Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab2002;87:3902–10.
74.
74. Hickner RC, Rosdahl H, Borg I, Ungerstedt U, Jorfeldt L, Henriksson J.Ethanol may be used with the microdialysis technique to monitor blood flow changes in skeletal muscle: dialysate glucose concentration is blood-flow-dependent. Acta Physiol Scand1991;143:355–6.
75.
75. Karpe F, Fielding BA, Ilic V, Humphreys SM, Frayn KN.Monitoring adipose tissue blood flow in man: a comparison between the (133)xenon washout method and microdialysis. Int J Obes Relat Metab Disord2002;26(1):1–5.
76.
76. Shipley RA, Clark RE.Tracer methods for in vivo kinetics. Theory and Applications. New York and London: Academic Press, 1972.
77.
77. Coppack SW, Persson M, Judd RL, Miles JM.Glycerol and nonesterified fatty acid metabolism in human muscle and adipose tissue in vivo. Am J Physiol1999;276(2 Pt 1):E233–E240.
78.
78. Klein S, Young VR, Blackburn GL, Bistrian BR, Wolfe RR.Palmitate and glycerol kinetics during brief starvation in normal weight young adult and elderly subjects. J Clin Invest1986;78(4):928–33.
79.
79. Coppack SW, Chinkes DL, Miles JM, Patterson BW, Klein S.A multi-compartmental model of in vivo adipose tissue glycerol kinetics and capillary permeability in lean and obese humans. Diabetes2005;54:1934–41.
80.
80. Tan GD, Fielding BA, Currie JM et al.The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia2005;48(1):83–95.
81.
81. Tan GD, Neville MJ, Liverani E et al.The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia2006;49:158–68.
82.
82. Coppack SW, Evans RD, Fisher RM et al.Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism1992;41:264–72.
83.
83. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN.Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci1996;91:679–83.
84.
84. Potts JL, Fisher RM, Humphreys SM, Coppack SW, Gibbons GF, Frayn KN.Peripheral triacylglycerol extraction in the fasting and post-prandial states. Clin Sci1991;81:621–6.
85.
85. Summers LK, Samra JS, Frayn KN.Impaired postprandial tissue regulation of blood flow in insulin resistance: a determinant of cardiovascular risk?. Athero1999;147:11–15.
87. Frayn KN, Shadid S, Hamlani R et al.Regulation of fatty acid movement in human adipose tissue in the postabsorptive-to-postprandial transition. Am J Physiol1994;266:E308–E317.
88.
88. Frayn KN.Adipose tissue as a buffer for daily lipid flux. Diabetologia2002;45:1201–10.
89.
89. Campbell PJ, Carlson MG, Nurjhan N.Fat metabolism in human obesity. Am J Physiol1994;266:E600–E605.
90.
90. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E.Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest1989;84:205–13.
91.
91. Skowronski R, Hollenbeck CB, Varasteh BB, Chen Y-DI, Reaven GM.Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabetic Med1991;8:330–3.
93. Ong JM, Kern PA.Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. J Clin Invest1989;84:305–11.
94.
94. Riemens SC, Sluiter WJ, Dullaart RP.Enhanced escape of non-esterified fatty acids from tissue uptake: its role in impaired insulin-induced lowering of total rate of appearance in obesity and Type II diabetes mellitus. Diabetologia2000;43:416–26.
95.
95. Forouhi NG, Jenkinson G, Thomas EL et al.Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia1999;42:932–5.
97. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW.Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes1991;40:280–9.
98.
98. Bjorntorp P.Liver triglycerides and metabolism. Int J Obes Relat Metab Disord1995;19:839–40.
99.
99. Goto T, Onuma T, Takebe K, Kral JG.The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord1995;19:841–5.
100.
100. Ryysy L, Hakkinen AM, Goto T et al.Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes2000;49:749–58.
101.
101. Paolisso G, Gambardella A, Amato L et al.Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia1995;38:1295–9.
102.
102. Zhou YP, Grill VE.Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest1994;93:870–6.
103.
103. Despres J-P, Nadeau A, Tremblay A et al.Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes1989;38:304–09.
104.
104. Marcus MA, Murphy L, Pi-Sunyer FX, Albu JB.Insulin sensitivity and serum triglyceride level in obese white and black women: relationship to visceral and truncal subcutaneous fat. Metabolism1999;48:194–9.
105.
105. Engfeldt P, Arner P.Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl1988;19:26–9.
106.
106. Ostman J, Arner P, Engfeldt P, Kager L.Regional differences in the control of lipolysis in human adipose tissue. Metabolism1979;28:1198–205.
107.
107. Richelsen B, Pedersen SB, Moller-Pedersen T, Bak JF.Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism1991;40:990–6.
108.
108. Frayn KN.Visceral fat and insulin resistance–causative or correlative?. Br J Nutr2000;83(suppl 1):S71–S77.
109.
109. Marin P, Rebuffe-Scrive M, Bjorntorp P.Uptake of triglyceride fatty acids in adipose tissue in vivo in man. Eur J Clin Invest1990;20:158–65.
110.
110. Guo Z, Hensrud DD, Johnson CM, Jensen MD.Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes1999;48:1586–92.
111.
111. Unger RH, Zhou YT, Orci L.Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA1999;96:2327–32.
112.
112. Oral EA, Simha V, Ruiz E et al.Leptin-replacement therapy for lipodystrophy. N Engl J Med2002;346:570–8.
113.
113. Arita Y, Kihara S, Ouchi N et al.Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun1999;257(1):79–83.
114.
114. Yamauchi T, Kamon J, Waki H et al.The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med2001;7:941–6.
115.
115. Tan GD, Debard C, Funahashi T et al.Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia2005;48:1585–9.
116.
116. Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS.Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes2002;51(6):1876–83.
117.
117. Mohamed-Ali V, Goodrick S, Rawesh A et al.Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-alpha, in vivo. J Clin Endo Metab1997;82:4196–200.
118.
118. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V.Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis2000;148:209–14.
119.
119. Esposito K, Pontillo A, Di Palo C et al.Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc2003;289:1799–804.
120.
120. Townsend RR.The effects of angiotensin-II on lipolysis in humans. Metabolism2001;50:468–72.
121.
121. Hennes MM, O'Shaughnessy IM, Kelly TM, LaBelle P, Egan BM, Kissebah AH.Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension1996;28:120–6.
122.
122. Boschmann M, Ringel J, Klaus S, Sharma AM.Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res2001;9:486–91.
123.
123. Goossens GH, Blaak EE, Saris WH, van Baak MA.Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab2004;89:2690–6.
124.
124. Goossens GH, McQuaid SE, Dennis AL et al.Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol2006;571 (Pt 2):451–60.
125.
125. Shimomura I, Funahashi T, Takahashi M et al.Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med1996;2:800–03.
126.
126. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H.Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism2000;49:666–71.
127.
127. Yudkin JS, Coppack SW, Bulmer K, Rawesh A, Mohamed-Ali V.Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thromb Res1999;96(1):1–9.
128.
128. Eriksson P, Van HV, Hoffstedt J et al.Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost2000;83:545–8.
129.
129. Mavri A, Alessi MC, Bastelica D et al.Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia2001;44:2025–31.
130.
130. Summers LK, Fielding BA, Ilic V, Quinlan PT, Frayn KN.The effect of triacylglycerol-fatty acid positional distribution on postprandial metabolism in subcutaneous adipose tissue. Br J Nutr1998;79:141–7.
131.
131. Summers LK, Fielding BA, Herd SL et al.Use of structured triacylglycerols containing predominantly stearic and oleic acids to probe early events in metabolic processing of dietary fat. J Lipid Res1999;40:1890–8.
132.
132. Summers LK, Barnes SC, Fielding BA, Beysen C et al.Uptake of individual fatty acids into adipose tissue in relation to their presence in the diet. Am J Clin Nutr2000;71:1470–7.
